Adult female patient treated with ABECMA® (idecabtagene vicleucel) with gray hair and glasses smiles while standing in a modern kitchen with a female child. Text reads “Choosing the right CAR T for me as soon as I’m eligible so I can keep baking with my granddaughter, –that’s my plan after ABECMA.” Mary, treated with ABECMA.

Mary was compensated by Bristol Myers Squibb for sharing her story.

ABECMA is only approved for use in adult patients. The safety and efficacy of ABECMA in patients under 18 years of age have not been established.

In a clinical study, at 30.9 months follow-up (median*), people treated with ABECMA lived without the disease getting worse or passing away (called progression-free survival) for 3 times longer (13.8 months compared with 4.4 months for those on standard treatments).

*Median is the middle number in a group of numbers arranged from lowest to highest.
CAR=chimeric antigen receptor.

It’s never too early to start discussing CAR T treatment with ABECMA

No matter where you are in your treatment journey, it's a good idea to ask your healthcare team about ABECMA and understand your options. Your doctor will consider many factors when deciding if ABECMA is right for you now—or in the future.

Two simple questions can help you determine whether or not it might be time for ABECMA:

Has your multiple myeloma come back (relapsed)?

– OR –

Did your multiple myeloma medicine not work (refractory)?

Have you tried 2 treatments that include a therapy from each of the 3 classes below?

Immunomodulatory Agent

Lenalidomide
(REVLIMID®)

Pomalidomide
(POMALYST®)

Thalidomide
(THALOMID®)

Proteasome Inhibitor

Bortezomib
(VELCADE®)

Carfilzomib
(KYPROLIS®)

Ixazomib
(NINLARO®)

Anti-CD38 Monoclonal Antibody

Daratumumab
(DARZALEX®)

Isatuximab-irfc
(SARCLISA®)

 

These medicines may be given by pill, injection, or infusion. Your doctor may have prescribed more than 1 at a time.
Please see product safety information at respective websites for the medicines listed above.

If you answered YES
to both of these questions or are unsure, you (or your loved one) may be eligible for ABECMA today.

If you answered NO
to either of these questions, ABECMA may still be an option for you in the future.

Whether you answered YES or NO, you should still talk with your doctor to see when ABECMA may fit into your treatment journey.

Your healthcare team will know what treatments have been previously prescribed to you and can help you determine whether or not you may be eligible for ABECMA.

What if I've received a stem cell transplant (SCT)?

ABECMA is not a stem cell transplant (SCT). ABECMA may be right for you even if you have had an SCT in the past.†

Learn more about how ABECMA is different from an SCT.

†85% to 92% of people in the ABECMA clinical trials had previously received an SCT.

Adult male and female patient treated with ABECMA® (idecabtagene vicleucel) couple smiling in a cozy, modern kitchen. On the right, a quote reads, “ABECMA is unlike any multiple myeloma treatment I’ve received before.” Cecilia, treated with ABCEMA.

Cecilia and her care partner were compensated by Bristol Myers Squibb for sharing their stories.

Are you caring for someone
receiving ABECMA?

Find a certified CAR T cell therapy treatment center near you

Important Facts About ABECMA®

(idecabtagene vicleucel)

This is a summary of important information that you need to know about ABECMA. Your healthcare team can work with you to help answer any questions you may have about this medication. Keep this document in a safe place, so you can refer to it before and during your treatment.

Look out for the following icons as you read:

Talk to your
healthcare team

Call a healthcare
provider right away

Helpful information
to remember

What is ABECMA?

ABECMA is a prescription medicine used to treat adults with relapsed or refractory multiple myeloma (MM), when:

you have tried two or more kinds of treatments that have not worked or have stopped working, AND

you have received at least one therapy from each of these drug classes:

  • an immunomodulatory agent
  • a proteasome inhibitor
  • an anti-CD38 antibody

WARNING: RISK OF SERIOUS SIDE EFFECTS

ABECMA may cause side effects that are life-threatening and can lead to death, including risk of cytokine release syndrome (CRS), neurologic toxicity, infections, low blood cell counts (cytopenia), and certain types of blood cancers.

Call your healthcare provider or get emergency help right away if you experience any of the following symptoms:

  • trouble breathing
  • fever (100.4°F/38°C or higher)
  • chills or shivering
  • confusion
  • feeling dizzy or lightheaded
  • shaking or twitching (tremor)
  • fast or irregular heartbeat
  • feeling severely tired or weak
  • severe nausea, vomiting, or diarrhea

Because of the risk of serious side effects, your healthcare provider will give you an ABECMA Patient Wallet Card that describes symptoms to look out for that require emergency medical care right away. It’s important that you tell your healthcare providers that you have received ABECMA and to show them your ABECMA Patient Wallet Card. Your healthcare provider may give you other medicines to treat your side effects.

How will I receive ABECMA?

ABECMA is a CAR (chimeric antigen receptor) T-cell therapy. It is a prescription medicine made using your own white blood cells. These white blood cells have been changed (genetically modified) to find and attack your multiple myeloma cells. ABECMA is given as an
intravenous (IV) infusion.

Before receiving your ABECMA infusion:

Your blood cells will be collected by a process called leukapheresis (LOO-kuh-feh-REE-sis), sometimes called apheresis.

Your blood cells will be sent to a manufacturing site to make your ABECMA. Based on clinical trial experience, your ABECMA will be ready to be shipped back to your healthcare provider about 4 weeks after your cells are received at the manufacturing site, but the time may vary.

Your healthcare provider will give you 3 days of chemotherapy to prepare your body before receiving your ABECMA treatment.

On the day of your ABECMA infusion:

You will receive ABECMA through a tube (catheter) placed into your vein (intravenous infusion). Your dose of ABECMA may be given in one or more infusion bags. Each infusion bag usually takes up to 30 min.

After receiving your ABECMA infusion:

For at least 1 week (7 days) after receiving ABECMA, you will stay at the facility where you received your treatment and be monitored daily.

For 2 weeks after receiving ABECMA, you should plan to stay close (within 2 hours) to the facility where you received your treatment. During this time, your healthcare provider will check to see that your treatment is working and help you with any side effects that may occur.

What should I avoid after receiving ABECMA?

Do not drive for at least 2 weeks after you get ABECMA.

Do not donate blood, organs, tissues, or cells for transplantation.

What are the possible or reasonably likely side effects of ABECMA?

Serious side effects

ABECMA can increase the risk of serious side effects. A serious side effect is a side effect that is severe or life-threatening and can lead to death. The serious side effects of ABECMA include, but are not limited to:

Early deaths. In a clinical study comparing ABECMA to standard treatments, a higher proportion of people died in the first 9 months from when they were assigned to receive ABECMA compared to people assigned to receive standard treatments. The higher rate of early death was seen before people received ABECMA, and the main reason was that their multiple myeloma had gotten worse. There was also an increase in the rate of death from side effects after receiving ABECMA.

Cytokine release syndrome (CRS). ABECMA can increase the risk of CRS, a very common side effect which can be severe or fatal. CRS happens when the immune system responds to an infection or a drug more aggressively than it should. Symptoms to look out for include:

  • fever (100.4°F/38°C or higher)
  • trouble breathing
  • dizziness or lightheadedness
  • nausea
  • headache
  • fast heartbeat
  • low blood pressure
  • feeling tired or weak

Infections. ABECMA can increase the risk of life-threatening infections that may lead to death. Symptoms to look out for include:

  • fever (100.4°F/38°C or higher)
  • chills
  • any other signs or symptoms of an infection

Low blood cell counts (cytopenia). ABECMA can lower the number of one or more types of your blood cells (red blood cells, white blood cells, or platelets), which may make you feel weak or tired, and could increase your risk of severe infection or bleeding. After treatment, your healthcare provider will test your blood to check for this. Symptoms to look out for include:

  • fever (100.4°F/38°C or higher)
  • feeling weak or tired
  • bruising
  • bleeding

Other (secondary) blood cancers. ABECMA may increase your risk of getting certain types of cancers, including certain types of blood cancers. You may hear your healthcare provider call these "secondary hematological malignancies."

Your healthcare provider should monitor you for any signs of secondary cancers.

ABECMA may cause a false-positive HIV (Human Immunodeficiency Virus) test result by some commercial tests.

Call your healthcare provider right away if you have any of these symptoms after receiving ABECMA. Remember to bring and show your ABECMA Patient Wallet Card to any healthcare provider who treats you.

Most common side effects

The most common side effects of ABECMA include:

  • feeling tired or weak
  • fever (100.4°F/38°C or higher)
  • chills or shivering
  • severe nausea or diarrhea
  • decreased appetite
  • headache
  • dizziness or lightheadedness
  • confusion
  • trouble speaking or slurred speech
  • cough
  • trouble breathing
  • fast or irregular heartbeat

These are not all of the possible side effects of ABECMA.

Talk to your healthcare team for medical advice about side effects. You are encouraged to report side effects to Bristol Myers Squibb at ABECMA.com or by calling 1-888-805-4555, or to the FDA by calling 1-800-FDA-1088.

For more information, please see the U.S. Full Prescribing Information, including Boxed WARNINGS, and Medication Guide for ABECMA. Talk to your healthcare provider for more information about this medication.

Bristol Myers Squibb logo   


Legal Notice  |  Privacy Policy  |  Your Privacy Choices   |  Contact Us  |  Site Map  


© 2025 Bristol-Myers Squibb Company.

ABECMA, CELL THERAPY 360, and the related logos are trademarks of Celgene Corporation, a Bristol Myers Squibb company. All other trademarks are the property of their respective owners. 2012-US-2500096 10/25 

This site is intended for U.S. audiences only.